Monthly Archive: January 2023

Early in my career as a general neurologist, there was no way to accurately make a diagnosis of Alzheimer’s disease in a living patient. The only way then to know for sure that a...

Today the FDA granted accelerated approval of the anti-amyloid monoclonal antibody lecanemab, now going by the trade name Leqembi. I have mixed feelings about this. Lecanemab is the only disease-modifying drug so far to...